Immunocore SVP logs sale and new equity awards

Immunocore Holdings plc executive John Goll reported both equity awards and a small tax-related share sale.

Rhea-AI Filing Summary

Immunocore Holdings plc executive John Goll reported both equity awards and a small tax-related share sale. As SVP, Finance & CAO, he sold 698 Ordinary Shares on February 18, 2026 in an open-market transaction at a weighted average price of $32.35 per share under a sell-to-cover arrangement to satisfy income tax liabilities from vesting restricted share units (RSUs).

On February 17, 2026, he acquired 1,351 Ordinary Shares through the exercise of RSUs, and received grants of 7,411 additional RSUs and 21,252 employee share options. The new RSUs and options vest in equal annual and quarterly installments beginning in February 2027, subject to his continuous service.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider GOLL JOHN

Role SVP, FINANCE & CAO

Sold 698 shs ($23K)

Approx. gross sale proceeds $23K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	698	$32.35	$23K
Exercise	Restricted Share Units	1,351	$0.00	$0.00
Grant/Award	Restricted Share Units	7,411	$0.00	$0.00
Grant/Award	Employee Share Option (Right to Buy)	21,252	$0.00	$0.00
Exercise	Ordinary Shares	1,351	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 11,465 contracts (Direct); Employee Share Option (Right to Buy) — 21,252 contracts (Direct); Ordinary Shares — 653 shares (Direct)

Footnotes (7)

1. F1. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.
2. F2. The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") .
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. Each RSU represents a contingent right to receive one Ordinary Share.
5. F5. On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.
6. F6. The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.
7. F7. 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IMCR executive John Goll report?

John Goll reported a small open-market sale and several equity awards. He sold 698 Ordinary Shares and acquired new RSUs and stock options, reflecting routine compensation activity and tax-related share sales tied to vesting restricted share units.

How many Immunocore (IMCR) shares did John Goll sell and at what price?

He sold 698 Ordinary Shares at a weighted average price of $32.35 per share. The sale occurred in multiple trades between $32.18 and $32.72 and was executed solely to cover income tax liabilities on RSU vesting.

Were John Goll’s IMCR share sales discretionary or tax-related?

The sale was tax-related under a sell-to-cover arrangement, not a discretionary liquidation. Shares were sold specifically to satisfy income tax liabilities triggered when previously granted restricted share units vested and converted into Ordinary Shares.

What new RSU awards did John Goll receive from Immunocore (IMCR)?

He received 7,411 new restricted share units, each representing a right to one Ordinary Share. These RSUs vest in four equal annual installments starting February 17, 2027, contingent on his continued service with Immunocore through each vesting date.

What stock options were granted to John Goll by Immunocore (IMCR)?

He was granted 21,252 employee share options, each giving the right to buy one Ordinary Share. Twenty-five percent vest on February 17, 2027, with 6.25% vesting quarterly thereafter, subject to his continued service at the company.

How did John Goll’s IMCR share ownership change after these transactions?

After selling 698 Ordinary Shares, he directly held 653 Ordinary Shares. Following the RSU conversion, he also directly held 4,054 RSUs, plus the newly granted 7,411 RSUs and 21,252 employee share options subject to future vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLL JOHN

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON, OXFORDSHIRE X0 OX14 4RY

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE & CAO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	02/17/2026		M		1,351	A	$0	1,351	D
Ordinary Shares(1)	02/18/2026		S		698(2)	D	$32.35(3)	653	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(4)	02/17/2026		M			1,351	(5)	(5)	Ordinary Shares(1)	1,351	$0	4,054	D
Restricted Share Units	(4)	02/17/2026		A		7,411		(6)	(6)	Ordinary Shares(1)	7,411	$0	7,411	D
Employee Share Option (Right to Buy)	$32.38	02/17/2026		A		21,252		(7)	02/16/2036	Ordinary Shares(1)	21,252	$0	21,252	D

Explanation of Responses:

1. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.

2. The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units ("RSUs") .

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $32.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Each RSU represents a contingent right to receive one Ordinary Share.

5. On February 17, 2025, the Reporting Person was granted 5,405 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

6. The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.

7. 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.